Ivarmacitinib provides rapid and continuous improvement in patients with moderate-to-severe atopic dermatitis: a focus on different anatomical regions.

OBJECTIVE

Ivarmacitinib (SHR0302) has demonstrated promising efficacy and safety profiles in patients with moderate-to-severe atopic dermatitis (AD). This study aimed to investigate the effects of ivarmacitinib on the extent and severity of moderate-to-severe AD across anatomical regions.

METHODS

A post-hoc analysis was performed based on the data from a phase III trial of ivarmacitinib (NCT04875169). Patients receiving ivarmacitinib or placebo were included in this study. Eczema Area and Severity Index (EASI) score was assessed in four regions, including the head/neck, upper extremities, trunk, and lower extremities. EASI 75/90/100 response was defined as ≥ 75.0%/90.0%/100.0% improvement in EASI score from baseline.

RESULTS

There were 112, 113, and 111 patients in the ivarmacitinib 8 mg, ivarmacitinib 4 mg, and placebo groups, respectively. Reductions in EASI scores from baseline for four regions (head/neck, upper extremities, trunk, and lower extremities) were greater in the ivarmacitinib 8 mg and 4 mg groups than in the placebo group at week (W) 1 and sustained until W16. Higher response rates of EASI 100, 90, and 75 across four regions were also observed in ivarmacitinib 8 mg and 4 mg groups versus the placebo group at W4, W8, W12 and W16. Moreover, most of the reductions in EASI erythema, edema/papulation, excoriation, and lichenification scores from baseline to W16 across four regions were greater in the ivarmacitinib 8 mg and 4 mg groups than in the placebo group.

CONCLUSION

Ivarmacitinib provides rapid and continuous improvement across all anatomical regions in patients with moderate-to-severe AD.